ARTL — Artelo Biosciences Inc
NASDAQ · Healthcare · Biotechnology
$6.45
+$0.29 (+4.77%)
Artelo Biosciences Inc (ARTL) is a biotechnology company listed on NASDAQ. It is led by Gregory D. Gorgas M.B.A., based in 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075, with about 5 employees. Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Net income was -$3.1M. ARTL currently screens at market cap $15.6M.
Use this ARTL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARTL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARTL SEC filings page. Lician reads the product cache first so this HTML stays unique to Artelo Biosciences Inc even when a live quote feed is slow.
About Artelo Biosciences Inc
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
ARTL Key Statistics
Market Cap
$15.58M
Volume
60,422
Previous Close
$0.72
Day Range
$0.71 – $0.73
EPS
-$3.05
Revenue
$0.00
Net Income
-$9.83M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
5
ARTL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.83M | -$9.29M | $10.08M | $4.04M |
| EPS (Diluted) | -$3.05 | -$3.14 | $0.00 | $0.00 |
Total Assets
$4.70M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$0.00
Operating Cash Flow
-$8.35M
Free Cash Flow
$0.00
Artelo Biosciences Inc Company Information
- President, CEO, CFO, Treasurer, Secretary & Director
- Gregory D. Gorgas M.B.A.
- Headquarters
- 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075
- Website
- www.artelobio.com
- Phone
- 858 925 7049
- IPO / Founded
- 2017-11-14
- Sector
- Healthcare
- Industry
- Biotechnology